Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03316573 |
| Title | A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas |
| Recruitment | Suspended |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Dana-Farber Cancer Institute |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Northwestern University | Chicago | Illinois | 60611 | United States | Details | |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States | Details | |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | United States | Details | |
| University of Nebraska | Omaha | Nebraska | 68198 | United States | Details |